Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 15;146(1):21–35. doi: 10.1161/CIRCULATIONAHA.121.056805

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Effect of MUFA and mixed UFA-rich diets vs a SFA-rich diet on risk-associated lipids in the DIVAS trial (Dietary Intervention and Vascular Function). A, Volcano plot of effect of diet intervention on within class-FA sum concentrations from a linear regression model with postintervention concentration as dependent variable and diet type (indicator variable for MUFA-rich [yes/no], mixed UFA-rich [yes/no], SFA-rich as reference), respective lipid baseline concentration, respective baseline, and postintervention class sum concentration, age, sex, and body mass index as independent variables. Direction of associations in the EPIC-Potsdam trial (European Prospective Investigation into Cancer and Nutrition) was consistent between type 2 diabetes and CVD for all risk-associated lipids. All labeled points were statistically significant after accounting for multiple testing. B, Word clouds for overlap between change through diet type and observed risk association in EPIC-Potsdam by disease. CE indicates cholesteryl esters; Cer, ceramides; CVD, cardiovascular disease; DG, diacylglycerols; dhCer, dihydroceramides; FA, fatty acids; FFA, free fatty acids; HexCer, hexosylceramides; LacCer, lactosylceramides; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; MG, monoacylglycerols; MUFA, monounsaturated fatty acid; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PEO, phosphatidylethanolamine ether; PEP, phosphatidylethanolamine plasmalogen; PI, phosphatidylinositol; SFA, saturated fatty acid; SM, sphingomyelins; TG, triacylglycerols; and UFA, unsaturated fatty acid.